Glesatinib companion diagnostic - Mirati Therapeutics/QIAGEN

Drug Profile

Glesatinib companion diagnostic - Mirati Therapeutics/QIAGEN

Latest Information Update: 28 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator QIAGEN
  • Class Diagnostic agents
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Non-small cell lung cancer

Most Recent Events

  • 28 Apr 2016 QIAGEN enters into a patnership with Mirati Therapeuticsto develop a companion diagnostic for treatment with glesatinib
  • 28 Apr 2016 Clinical in Non-small cell lung cancer (Diagnosis) in USA, Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top